Regeneron's Eylea Soars, But Praluent Is Slow Out Of The Gate
This article was originally published in The Pink Sheet Daily
Biotech points to slow reimbursement pace in the US for PCSK9 inhibitors, but the bigger issue may be awaiting CV outcomes data. Eylea continued its exponential sales growth, however, as Regeneron seeks to add to its label.
You may also be interested in...
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.
In the age of coronavirus, human factors professionals are doing their best to find their way through the pandemic by putting unique twists on usability testing to see what works and what doesn’t in the new reality. That’s the topic of this week’s podcast.